EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study

Onkofertilitätsversorgung von 599 Kindern und Jugendlichen mit Krebs und hohem Risiko behandlungsbedingter Gonadenschäden: nationale pädiatrische Kohortenstudie

N H Z Clasen iD, M E M van der Perk, S L Broer, J van Leeuwen, C H E Weimar, I M IJgosse, J Rascon, A J Klijn, A L F van der Kooi, A F W van der Steeg, S J C M M Neggers, M A Veening und 3 weitere

Human Reproduction · 01.11.2026 · 41 (11) · 1932-1944

DOI: 10.1093/humrep/deag138 ↗

Auf einen Blick

Bei 599 Kindern und Jugendlichen mit hohem Risiko für Gonadenschäden war eine standardisierte, personalisierte Onkofertilitätsversorgung bei 66,1 % umgesetzt. Von diesen erhielten 60,1 % Maßnahmen zur Fertilitätserhaltung.

Fragestellung

Wie gut ist die standardisierte Onkofertilitätsversorgung mit Fokus auf Fertilitätsberatung und Fertilitätserhaltung bei Kindern und Jugendlichen mit Krebs und hohem Risiko für Gonadenschäden?

Methode

Deskriptive Kohortenstudie in einem nationalen prospektiven Kollektiv am Princess Máxima Center; Auswertung von Januar 2020 bis Dezember 2023; prospektive Erfassung und retrospektive Analyse von Gründen für fehlende Beratung oder Fertilitätserhaltung.

Ergebnisse

599 Patient:innen wurden als HRgd eingestuft (0–23 Jahre; 345 männlich, 254 weiblich). 396 (66,1 %) wurden beraten; 238 davon (60,1 %) erhielten Fertilitätserhaltung. Gründe für fehlende Beratung: klinischer Status, junges Alter, schlechte Prognose.

Einschränkungen

Triage-Informationen zu Patient:innen aus der Aufbauphase der Onkofertilitätsversorgung könnten noch fehlen.

Schlussfolgerung der Autor:innen

Weitere Verbesserungen der Onkofertilitätsversorgung sind nötig, einschließlich Beratung aller HRgd-Patient:innen und standardisierter Dokumentation zur Gonadenerhaltung, wann immer anwendbar.

Kernaussagen

  • 66,1 % der HRgd-Patient:innen erhielten eine Beratung
  • 60,1 % der Beratenen durchliefen Fertilitätserhaltung
  • Gründe gegen Beratung oder Maßnahmen waren klinischer Status, Alter und Prognose

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 07.09.2026. Verfasst von N H Z Clasen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Fertility Preservation, Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Princess Máxima Center for Pediatric Oncology, Twinning in Research and Education to improve survival, Education and Twinning (SCARLET).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY QUESTION What is the quality of our standard oncofertility care, with a focus on fertility counselling and preservation rates, in children and adolescents with cancer and a high risk of treatment-induced gonadal damage (HRgd) at our national centralised paediatric oncology centre? SUMMARY ANSWER Standardised personalised oncofertility care was achieved in 66.1% of identified HRgd children and adolescents with cancer, of whom 60.1% of patients underwent fertility preservation methods. WHAT IS KNOWN ALREADY Increasing survival rates among childhood cancer patients have heightened awareness of long-term treatment-related toxicities, including gonadal damage and subsequent risk of infertility. The American Society for Reproductive Medicine and the International Guideline Harmonization Group recommend that fertility preservation counselling should be offered to paediatric and adolescent cancer patients at high risk of gonadal damage, including consideration of gonadal tissue preservation when appropriate. However, evidence on the implementation of oncofertility care programmes in HRgd paediatric and adolescent cancer patients remains limited. STUDY DESIGN, SIZE, DURATION This descriptive cohort study reports on standard oncofertility care in a national prospective cohort of HRgd childhood cancer patients, between January 2020 and December 2023, in our national paediatric oncology centre. PARTICIPANTS/MATERIALS, SETTING, METHODS In all HRgd childhood cancer patients, who were diagnosed or relapsed between January 2020 and December 2023 in the Princess Máxima Center, our standard oncofertility care strategy was evaluated. Prospective collection of demographics, tumours, treatment, and oncofertility care details, as well as retrospective collection and analysis of reasons why HRgd patients and their families were not counselled or did not undergo fertility preservation, was performed. MAIN RESULTS AND THE ROLE OF CHANCE Between January 2020 and December 2023, 599 patients (age range 0–23 years; 345 males, 254 females) were triaged as HRgd (459 children newly diagnosed and 140 relapsed patients), including 396 (66.1%) who were counselled with 238 of these (60.1%) undergoing fertility preservation. Reasons why HRgd patients did not receive fertility counselling (n = 203/599, 34%) included their clinical status at diagnosis, young age of the patient, and anticipated poor prognosis. Uncertainties regarding future reproductive outcomes after autotransplantation of preserved tissue and concerns about potential risks of preservation procedures, were reasons for HRgd patients (n = 158/396, 40%) to refrain from fertility preservation. LIMITATIONS, REASONS FOR CAUTION Triage information of HRgd patients who were diagnosed and/or relapsed during the establishment of oncofertility care in our centre may still be lacking. WIDER IMPLICATIONS OF THE FINDINGS Further improvement in oncofertility care is warranted by counselling all HRgd patients and offering all of them gonadal tissue preservation through standardised documentation, whenever applicable. Future knowledge on reproductive and safety outcomes after cryopreservation and autotransplantation of gonadal tissue will further enhance fertility counselling. FUNDING This project is cofounded by funding from the Princess Máxima Center for Pediatric Oncology, the Twinning in Research and Education to improve survival in childhood solid tumours in Lithuania (TREL) project (H2020-EU.4.b grant number 952438), and SCAling up early and late effects Research in Lithuanian childhood cancer survivors through Education and Twinning (SCARLET) project (Horizon CSA grant number 10119949). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DISCLOSURES The authors have declared that no competing interests exist. TRIAL REGISTRATION NUMBERS METC research file NL72115.041.19 (METC-protocol number 19/783, Netherlands trial register number NL8192); METC research file NL73818.000.21 (METC-protocol number 0000002974).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fertility PreservationNeoplasmsHumansAdolescentChildMaleFemaleChild, PreschoolInfantCohort StudiesCounselingProspective StudiesYoung Adult

Stichwörter der Autor:innen

childhood cancercounsellingfertility preservationgonadal damageoncofertility

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Department of Pediatric Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden,The Netherlands.

ORCID-Profile: N H Z Clasen, M M van den Heuvel-Eibrink

Förderung

  • Princess Máxima Center for Pediatric Oncology
  • Twinning in Research and Education to improve survival
  • Education and Twinning (SCARLET)

Zitieren

APA

Clasen, N. H. Z., van der Perk, M. E. M., Broer, S. L., van Leeuwen, J., Weimar, C. H. E., IJgosse, I. M., Rascon, J., Klijn, A. J., van der Kooi, A. L. F., van der Steeg, A. F. W., Neggers, S. J. C. M. M., Veening, M. A., Bos, A. M. E., van de Wetering, M. D., & van den Heuvel-Eibrink, M. M. (2026). Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study. Human Reproduction, 41(11), 1932-1944. https://doi.org/10.1093/humrep/deag138

Vancouver

Clasen NHZ, van der Perk MEM, Broer SL, van Leeuwen J, Weimar CHE, IJgosse IM, et al. Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study. Human Reproduction. 2026;41(11):1932-1944. doi:10.1093/humrep/deag138

BibTeX
@article{Clasen2026,
  author = {Clasen, N H Z and van der Perk, M E M and Broer, S L and van Leeuwen, J and Weimar, C H E and IJgosse, I M and Rascon, J and Klijn, A J and van der Kooi, A L F and van der Steeg, A F W and Neggers, S J C M M and Veening, M A and Bos, A M E and van de Wetering, M D and van den Heuvel-Eibrink, M M},
  title = {Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {11},
  pages = {1932--1944},
  doi = {10.1093/humrep/deag138}
}
Kostenlos starten →